6-K ·Filed Apr 23, 2026
Notable filing: 6-K
Actionable Insight ◆ Mixed
Monitor upcoming data readouts from mid-2026, which could be catalysts, but watch for potential equity financing given the tight cash position.
Final — all horizons settled through T+60d
RDPTF ▼ -50.00% at T+60d
NEUTRAL call -50.00% · α vs SPY -55.02% · entry $0.0200 → $0.0100
T+1d
0.00%
call 0.00% · α -0.78%
$0.0200
settled 6mo ago
T+5d
0.00%
call 0.00% · α -1.48%
$0.0200
settled 6mo ago
T+20d
0.00%
call 0.00% · α -4.63%
$0.0200
settled 5mo ago
T+60d
-50.00%
call -50.00% · α -55.02%
$0.0100
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Radiopharm Theranostics reported strong clinical progress across its pipeline, including completion of enrollment in a Phase 2b trial for RAD101 and positive interim data for RAD202. However, the company's cash reserves dropped significantly from $34.5M to $19.2M in the quarter, raising near-term funding concerns.
Key Facts
- Completed enrollment in Phase 2b trial for RAD101 imaging agent
- Presented positive initial Phase 0/1 data for RAD202 at AACR
- Received positive recommendation from DSMB to advance RAD202 to next dose level
- Initiated two First-In-Human clinical trials for RV-01 and RAD402
- Closing cash decreased from $34.5M to $19.2M in the quarter
- Estimated quarters of funding available dropped to 1.29
Financial Impact
Cash burn of $14.9M in the quarter, reducing cash reserves by $15.3M
cashcash burn rate
Risk Factors
- Insufficient cash runway to fund operations without additional financing
- Clinical trial delays could impact valuation
- Dilution risk from potential equity financing
Market Snapshot
Exchange
OTC
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-046883 |
| Document: ea0287455-6k_radio.htm | 0001213900-26-046883 |
| Document: 0001213900-26-046883-index-headers.html | 0001213900-26-046883 |
| Document: 0001213900-26-046883-index.html | 0001213900-26-046883 |
| Document: 0001213900-26-046883.txt | 0001213900-26-046883 |
8 reports for RDPTF
0% Hit rate @ T+60 Went positive at some point 0 of 4 best @ T+1· 0.00%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 20w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −52.50% | $0.006660 (−66.70%) |
May 6, 2026 24w ago | 3 | $0.0200 $0.0100 | ▼ −50.00% | ▼ −53.83% | $0.006660 (−66.70%) |
Apr 23, 2026 26w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −55.02% | $0.006660 (−66.70%) |
Apr 16, 2026 27w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −57.05% | $0.006660 (−66.70%) |
Apr 8, 2026 28w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −60.46% | $0.006660 (−66.70%) |
Apr 7, 2026 28w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −63.27% | $0.006660 (−66.70%) |
Apr 1, 2026 29w ago | 3 | $0.0200 $0.0100 | ▼ −50.00% | ▼ −64.16% | $0.006660 (−66.70%) |
Mar 27, 2026 30w ago | 6-K | $0.0200 $0.0200 | · 0.00% | ▼ −16.07% | $0.006660 (−66.70%) |
Showing 8 of 8
US Market Status
Market Open — Closes in 1h 6m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers